Page last updated: 2024-11-04

arecoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
ArecagenusA plant genus of the family ARECACEAE. Members contain ARECOLINE and CATECHIN. The leaves and nuts have been used as masticatories, stimulants, and astringents in traditional medicine. The common name of betel is also used for PIPER BETLE. The common name of catechu is sometimes used for ACACIA CATECHU.[MeSH]ArecaceaeThe palm family of order Arecales, subclass Arecidae, class Liliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID2230
CHEMBL ID7303
CHEBI ID2814
SCHEMBL ID44065
MeSH IDM0001674

Synonyms (137)

Synonym
BRD-K88646909-004-06-3
BRD-K88646909-004-05-5
methyl 1-methyl-5,6-dihydro-2h-pyridine-3-carboxylate
gtpl296
nicotinic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester
KBIO1_000810
DIVK1C_000810
smr000058258
MLS000028840 ,
SDCCGMLS-0066647.P001
1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxylic acid methyl ester
methyl n-methyl-1,2,5,6-tetrahydronicotinate
methyl n-methyltetrahydronicotinate
n-methyltetrahydropyridine-beta-carboxylic acid methyl ester
brn 0123045
1,2,5,6-tetrahydro-1-methylnicotinic acid, methyl ester
methyl 1,2,5,6-tetrahydro-1-methylnicotinate
methylarecaiden
arekolin
ccris 7688
einecs 200-565-5
arecholin
1-methyl-delta(sup 3,4)tetrahydro-3-pyridinecarboxylate
nsc 56321
n-methyltetrahydropyridine-.beta.-carboxylic acid methyl ester
arecaidine methyl ester
arecolin
arecholine
3-pyridinecarboxylic acid,2,5,6-tetrahydro-1-methyl-, methyl ester
methyl n-methyl-1,5,6-tetrahydronicotinate
nsc-56321
methylarecaidin
nsc56321
methyl 1,5,6-tetrahydro-1-methylnicotinate
arecaline
n-methyltetrahydronicotinic acid, methyl ester
wln: t6n cutj a1 cvo1
nicotinic acid,2,5,6-tetrahydro-1-methyl-, methyl ester
1,5,6-tetrahydro-1-methylnicotinic acid, methyl ester
arecoline base
n-methyl-.delta.-tetrahydronicotinic acid methyl ester
SPECTRUM_000055
BSPBIO_002974
ACON1_002372
c8h13no2
NCGC00015075-02
NCGC00015075-01
lopac-a-6134
cas-300-08-3
PRESTWICK2_000402
BSPBIO_000324
LOPAC0_000049
BPBIO1_000358
SPECTRUM5_001316
MEGXP0_001891
1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxylic acid, methyl ester
inchi=1/c8h13no2/c1-9-5-3-4-7(6-9)8(10)11-2/h4h,3,5-6h2,1-2h
3-pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester
methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate
methyl 1-methyl-3,6-dihydro-2h-pyridine-5-carboxylate
arecoline
63-75-2
DB04365
IDI1_000810
NCGC00162053-02
KBIO3_002194
KBIO2_000435
KBIO2_003003
KBIOSS_000435
KBIOGR_001299
KBIO2_005571
PRESTWICK1_000402
SPECTRUM4_000810
SPBIO_000201
NINDS_000810
PRESTWICK0_000402
SPECTRUM3_001387
SPBIO_002263
SPECTRUM2_000051
PRESTWICK3_000402
NCGC00162053-01
NCGC00162053-03
NCGC00015075-06
AKOS000520752
L000795
chebi:2814 ,
CHEMBL7303
NCGC00015075-04
A820142
n-methyltetrahydronicotinicacidmethylesterhydrobromide
tox21_110079
cas-63-75-2
dtxcid502617
dtxsid3022617 ,
CCG-204145
NCGC00015075-03
NCGC00015075-07
NCGC00015075-05
4aln5933bh ,
unii-4aln5933bh
FT-0622470
arecoline [mi]
SCHEMBL44065
tox21_110079_1
NCGC00015075-10
1-methyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester
methyl 1-methyl-3,6-dihydro-2h-pyridine-5-carboxylate;hydrobromide
arecoline;hydrobromide
cid_9301
1-methyl-3,6-dihydro-2h-pyridine-5-carboxylic acid methyl ester;hydrobromide
bdbm46858
methylarecaidine
methyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate #
AC-34025
BBL036229
AB00053580_08
AB00053580_09
SR-01000075307-9
SBI-0050038.P003
arecoline_major
n-methyl-beta -carboxylic acid methyl ester
methyl n-methyl-1,2,5, 6-tetrahydronicotinate
methyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate
methyl 1,2,5, 6-tetrahydro-1-methylnicotinate
Q423515
BRD-K88646909-004-10-5
A13071
SDCCGSBI-0050038.P004
NCGC00015075-19
arecaidine methyl ester;arecoline base;methyl arecaidin; methylarecaidine; nsc56321
63-75-2 (free)
SB54186
?arecoline
EN300-40737
pyranosyl)-?-d-galactopyranoside
4-nitrophenyl 2-acetamido-2-deoxy-(6-o-2-acetamido-2-deoxy-?-d-gluco-
mfcd00059167

Research Excerpts

Overview

Anceline is a well-known risk factor for oral submucosal fibrosis and cancer. It is a muscarinic alkaloid in areca nut, which we earlier reported ca. Arecoline has been employed to induce the elevated myofibroblast activity in humans.

ExcerptReferenceRelevance
"Arecoline is a well-known risk factor for oral submucosal fibrosis and cancer. "( Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway.
Chen, H; Dai, H; Jing, R; Liao, X; Pan, L; Xie, H; Xie, X, 2022
)
3.61
"Arecoline is a critical bioactive component in areca nuts with toxicity and pharmacological activities. "( Short-term arecoline exposure affected the systemic health state of mice, in which gut microbes played an important role.
Hu, X; Jiang, S; Li, W; Su, S; Xu, M; Zhang, J; Zhang, Z, 2023
)
2.74
"Arecoline is an alkaloid extracted from betel nut, which has various pharmacological effects. "( Arecoline aggravates acute ulcerative colitis in mice by affecting intestinal microbiota and serum metabolites.
Chen, Y; Ding, T; Liu, D; Rao, J; Yang, W; Yi, B; Zhao, H, 2023
)
3.8
"Arecoline is a nicotinic acetylcholine receptor agonist expressed in Xenopus oocytes."( Betel quid dependence mechanism and potential cessation therapy.
Ko, AM; Ko, YC; Lee, CH, 2020
)
1.28
"Arecoline is a naturally occurring psychoactive alkaloid with partial agonism at nicotinic and muscarinic acetylcholine receptors. "( Effects of acute and chronic arecoline in adult zebrafish: Anxiolytic-like activity, elevated brain monoamines and the potential role of microglia.
Alpyshov, ET; Amstislavskaya, TG; Babashev, AM; de Abreu, MS; Demin, KA; Efimova, EV; Gainetdinov, RR; Galstyan, D; Hu, G; Kalueff, AV; Kolesnikova, TO; Mor, MS; Serikuly, N; Song, C; Strekalova, T; Wang, D; Wang, J; Yan, D; Yang, L, 2021
)
2.36
"Arecoline is an alkaloid natural product found in the areca nut that can induce oral submucous fibrosis and subsequent development of cancer. "( Egr-1 mediates low-dose arecoline induced human oral mucosa fibroblast proliferation via transactivation of Wnt5a expression.
Chen, Q; Chen, Z; He, S; Jiao, J; Li, X; Mai, Z; Ren, J; Wang, Y, 2020
)
2.31
"Arecoline is a major areca nut alkaloid and has been employed to induce the elevated myofibroblast activity in human buccal mucosal fibroblasts (BMFs)."( miR-200b ameliorates myofibroblast transdifferentiation in precancerous oral submucous fibrosis through targeting ZEB2.
Chang, YC; Hsieh, PL; Liao, YW; Yu, CC, 2018
)
1.2
"Arecoline is a naturally occurring psychoactive alkaloid from areca (betel) nuts of the areca palm ( Areca catechu) endemic to South and Southeast Asia. "( DARK Classics in Chemical Neuroscience: Arecoline.
Alpyshov, ET; Amstislavskaya, TG; Bashirzade, A; Demin, KA; Ho, YJ; Kalueff, AV; Lakstygal, AM; Serikuly, N; Shevyrin, VA; Tang, Z; Volgin, AD; Wang, D; Wang, J; Wang, M; Wappler-Guzzetta, EA; Yakovlev, OA; Yan, D, 2019
)
2.22
"Arecoline is a muscarinic alkaloid in areca nut, which we earlier reported causes injury and necrosis of human endothelium."( Arecoline increases basic fibroblast growth factor but reduces expression of IL-1, IL-6, G-CSF and GM-CSF in human umbilical vein endothelium.
Cox, S; Kelly, E; Moore, MA; Ullah, M; Zoellner, H, 2015
)
2.58
"Arecoline (ARE) is an alkaloid-type natural product from areca nut. "( Arecoline inhibits intermediate-conductance calcium-activated potassium channels in human glioblastoma cell lines.
Hsing, CH; Huang, YM; Liao, YK; So, EC; Wu, SN, 2015
)
3.3
"Arecoline is known to be a relatively non-selective muscarinic partial agonist, accounting for many of the overt peripheral and central nervous system effects, but not likely to account for the addictive properties of the drug."( Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity.
Horenstein, NA; Papke, RL; Stokes, C, 2015
)
1.45
"Arecoline is an effective constituent of Areca catechu L. "( The pharmacology, toxicology and potential applications of arecoline: a review.
Hu, MB; Liu, YJ; Peng, W; Wu, CJ; Xu, M, 2016
)
2.12
"Arecoline is a major alkaloid of areca nut and has been effect on central nervous system. "( Arecoline Induces Neurotoxicity to PC12 Cells: Involvement in ER Stress and Disturbance of Endogenous H2S Generation.
Chen, Y; Gu, HF; Guo, RM; Jiang, JM; Tang, XQ; Wang, L; Wu, K; Xiao, F, 2016
)
3.32
"Arecoline is a plant alkaloid of betel nut Areca catechu. "( Ultrastructural and hormonal modulations of the thyroid gland following arecoline treatment in albino mice.
Chatterji, U; Chaudhuri-Sengupta, S; Dasgupta, R; Maiti, BR; Nag, D; Nag, TC, 2010
)
2.04
"Arecoline is an alkaloid-type natural product found in betel nuts."( Betel nut extract and arecoline block insulin signaling and lipid storage in 3T3-L1 adipocytes.
Chang, WC; Chou, PC; Hsiao, PJ; Hsieh, PC; Hsieh, TJ; Lin, KD; Shin, SJ; Wu, MT, 2011
)
1.41
"Arecoline is an effective component of areca (betel nuts, a Chinese medicine named pinang or binglang). "( Arecoline excites the colonic smooth muscle motility via M3 receptor in rabbits.
Chen, LB; Liu, CY; Liu, KJ; Wang, PS; Xie, DP; Zhang, CL, 2004
)
3.21
"Arecoline is an alkaloid of betel nut of Areca catechu. "( Ultrastructural and hormonal changes in the pineal-testicular axis following arecoline administration in rats.
Banerjee, S; Chatterji, U; Chaudhuri-Sengupta, S; Maiti, BR; Nag, D; Nag, TC; Saha, I, 2007
)
2.01
"Arecoline is a muscarinic receptor agonist."( Arecoline cytotoxicity on human oral mucosal fibroblasts related to cellular thiol and esterase activities.
Hahn, LJ; Jeng, JH; Kuo, MY; Kuo, YS; Tsai, CL; Yang, PJ, 1999
)
2.47

Effects

Anceline hydrobromide has been used for almost half a century for the treatment of Echinococcus granulosus in dogs. Arecoline has immunosuppressive, mutagenic and genotoxic effects in laboratory animals.

ExcerptReferenceRelevance
"Arecoline has been reported to be the primary toxic constituent in the areca nut."( Arecoline induces cardiotoxicity by upregulating and activating cardiac hypertrophy-related pathways in Sprague-Dawley rats.
Chen, RJ; Chi-Kang Tsai, B; Day, CH; Ho, TJ; Huang, CY; Jine-Yuan Hsieh, D; Kumar, VB; Kuo, CH; Kuo, WW; Luk, HN; Yao, CH, 2022
)
2.89
"Arecoline has biomedical importance, but it has untoward side effects on endocrine functions. "( Arecoline plays dual role on adrenal function and glucose-glycogen homeostasis under thermal stress in mice.
Dasgupta, R; Maiti, BR; Maity, A; Pradhan, D; Ray, PP; Saha, I; Sarkar, HP, 2020
)
3.44
"Arecoline has great potential to be a therapeutic drug for various ailments. "( The pharmacology, toxicology and potential applications of arecoline: a review.
Hu, MB; Liu, YJ; Peng, W; Wu, CJ; Xu, M, 2016
)
2.12
"Arecoline has immunosuppressive, hepatotoxic, mutagenic and teratogenic effects, and disturbs some endocrine organs in rats."( Ultrastructural and hormonal modulations of the thyroid gland following arecoline treatment in albino mice.
Chatterji, U; Chaudhuri-Sengupta, S; Dasgupta, R; Maiti, BR; Nag, D; Nag, TC, 2010
)
1.31
"Arecoline has been proved the most effect-increasing component."( [Studies on the effect-increasing components for molluscacides in nut of Areca catech L].
Feng, Q; Gao, J; Li, GL; Yang, Y, 2000
)
1.75
"Arecoline has immunosuppressive, mutagenic and genotoxic effects in laboratory animals."( Ultrastructural and hormonal changes in the pineal-testicular axis following arecoline administration in rats.
Banerjee, S; Chatterji, U; Chaudhuri-Sengupta, S; Maiti, BR; Nag, D; Nag, TC; Saha, I, 2007
)
1.29
"Arecoline hydrobromide has been used for almost half a century for the treatment of Echinococcus granulosus in dogs. "( Surveillance of Echinococcus granulosus in dogs with arecoline hydrobromide.
Gemmell, MA, 1973
)
1.94

Actions

Arecoline did produce significant alterations of blood pressure, heart rate, and body temperature. Arecoline-elicited increase in intracellular Ca(2+) concentration was responsible for JNK/c-Jun pathway activation and ERK inactivation.

ExcerptReferenceRelevance
"Arecoline plays an important role in the pathogenesis of OSF."( Cytokines secreted by arecoline activate fibroblasts that affect the balance of TH17 and Treg.
Gu, L; Tang, Z; Wang, L, 2020
)
1.59
"Arecoline is known to cause endocrine dysfunction. "( Arecoline inhibits pineal-testis function in experimentally induced hypothyroid rats.
Chakraborty, SB; Chatterjee, A; Chatterji, U; Maiti, BR; Pradhan, D; Saha, I, 2020
)
3.44
"Arecoline-elicited increase in intracellular Ca(2+) concentration was responsible for JNK/c-Jun pathway activation and ERK inactivation."( Arecoline-induced death of human leukemia K562 cells is associated with surface up-modulation of TNFR2.
Chang, LS; Chen, YJ, 2012
)
2.54
"Arecoline could increase the expression of hTERT mRNA and protein in oral keratinocytes. "( [Effects of arecoline and nicotine on the expression of hTERT in oral keratinocytes].
Gao, YJ; Huang, Y; Li, X; Ling, TY; Yin, XM, 2007
)
2.16
"Arecoline proved to cause changes in the electrolyte distribution by the depolarization type, whereas amizyl--by the type of hyperpolarization of the nerve cell membrane."( [Effect of amizil and arecoline on the activity of Na, K-ATP-ase and concentration of Na+ and K+ ions in rat brain].
Krylov, SS; Petrov, AN; Semenov, EV, 1977
)
1.29
"Arecoline did produce significant alterations of blood pressure, heart rate, and body temperature, probably by central cholinergic stimulation."( Treatment of Huntington disease with a cholinergic agonist.
Chase, TN; Nutt, JG; Rosin, A, 1978
)
0.98

Treatment

Arecoline treatment (10 mg/kg body wt/day, for 7 d) caused a reduction in thyroid weight and ultrastructural degeneration of thyro-follicular cells. In arecoline-treated OSCC cells, oncostatin M (OSM) expression was significantly upregulated and inversely correlated with miR-22 expression.

ExcerptReferenceRelevance
"Arecoline treatment upregulated the expression of phosphorylated extracellular signal-regulated kinase through epithelial mesenchymal transition and renal fibrosis in HK2 cells."( Arecoline induces epithelial mesenchymal transition in HK2 cells by upregulating the ERK-mediated signaling pathway.
Cheng, CW; Hsieh, YH; Lee, CC; Lee, CH; Lin, SH; Syu, RJ; Tsai, JP, 2020
)
2.72
"Arecoline treatment in vitro at low concentrations and overexpression of HPV16 E6 or E6/E7 in oral cells induced PRDX2 overexpression."( Peroxiredoxin 2 is highly expressed in human oral squamous cell carcinoma cells and is upregulated by human papillomavirus oncoproteins and arecoline, promoting proliferation.
Chuerduangphui, J; Ekalaksananan, T; Heawchaiyaphum, C; Pientong, C; Vatanasapt, P, 2020
)
1.48
"Arecoline treatment in noise exposure showed same results as in noise both in pineal and in reproductive functions."( Arecoline cannot alter testicular dysfunction and pineal activation caused by noise in wistar rat.
Chatterjee, A; Chatterji, U; Maiti, BR; Saha, I, 2018
)
2.64
"Arecoline treatment (10 mg/kg body wt/day, for 7 d) caused a reduction in thyroid weight and ultrastructural degeneration of thyro-follicular cells with depletion of T"( Arecoline ameliorates hyperthyroid condition in mice under cold stress.
Dasgupta, R; Maiti, BR; Maity, A; Ray, PP; Saha, I, 2018
)
2.64
"In arecoline-treated OSCC cells, oncostatin M (OSM) expression was significantly upregulated and inversely correlated with miR-22 expression."( Effects of arecoline on proliferation of oral squamous cell carcinoma cells by dysregulating c-Myc and miR-22, directly targeting oncostatin M.
Chaiyarit, P; Chotiyano, A; Chuerduangphui, J; Ekalaksananan, T; Kongyingyoes, B; Patarapadungkit, N; Pientong, C; Promthet, S, 2018
)
1.38
"Arecoline treatment dose-dependently reduced the relative expression of miR-200c in normal BMFs."( miR-200c inhibits the arecoline-associated myofibroblastic transdifferentiation in buccal mucosal fibroblasts.
Chen, PY; Hsieh, PL; Liao, YW; Lin, KH; Lu, MY; Peng, CY; Yu, CC; Yu, CH, 2018
)
1.52
"Arecoline treatment alone, or in cold or heat stress suppressed adrenomedullary activity, judged by ultrastructural and hormonal parameters."( Arecoline plays dual role on adrenal function and glucose-glycogen homeostasis under thermal stress in mice.
Dasgupta, R; Maiti, BR; Maity, A; Pradhan, D; Ray, PP; Saha, I; Sarkar, HP, 2020
)
2.72
"Arecoline treatment for 10 days at a dose of 10 mg/kg of body weight markedly facilitated β-cell regeneration and reversed testicular and sex accessory dysfunctions by increasing the levels of serum insulin and gonadotropins in type 1 diabetic rats. "( A protective role of arecoline hydrobromide in experimentally induced male diabetic rats.
Chatterji, U; Das, J; Maiti, B; Saha, I, 2015
)
2.18
"Arecoline treatment dose dependently induced Lin28B expression in SG and FaDu cells."( Elevated Lin28B expression is correlated with lymph node metastasis in oral squamous cell carcinomas.
Chou, MY; Lin, WT; Shieh, TM; Wang, TY; Yang, LC; Yu, CC, 2015
)
1.14
"Arecoline treatment led to an increase in the number of rough endoplasmic reticulum and reduction of secretory vesicles, signifying a hyperactive state of the prostate."( Arecoline augments cellular proliferation in the prostate gland of male Wistar rats.
Chatterjee, A; Chatterji, U; Maiti, BR; Mondal, A; Saha, I, 2011
)
2.53
"Arecoline treatment induced death of K562 cells and increased surface expression of TNFα, TNFR1, and TNFR2."( Arecoline-induced death of human leukemia K562 cells is associated with surface up-modulation of TNFR2.
Chang, LS; Chen, YJ, 2012
)
2.54
"Arecoline treatment improves ACh-induced EDVR in high fructose-fed rats, and the potential mechanism of action might be associated with increase of CSE expression and activation of K(ATP) channels by arecoline."( Arecoline improves vascular endothelial function in high fructose-fed rats via increasing cystathionine-γ-lyase expression and activating K(ATP) channels.
Hu, B; Li, X; Ling, HY; Wang, G; Zhang, W; Zhou, SH, 2012
)
3.26
"Arecoline-treated embryos exhibited general developmental retardation in a dose-dependent manner. "( Developmental toxicity of arecoline, the major alkaloid in betel nuts, in zebrafish embryos.
Chang, BE; Chen, CH; Kuo, MY; Liao, MH, 2004
)
2.07
"Arecoline treatment (10 mg/kg body weight daily for 10 days) caused suppression of pineal activity at ultrastructural level by showing dilatation of the cisternae of the rough endoplasmic reticulum (RER), large autophagosome-like bodies with swollen mitochondrial cristae, numerous lysosomes, degenerated synaptic ribbons and reduced number of synaptic-like microvesicles."( Ultrastructural and hormonal changes in the pineal-testicular axis following arecoline administration in rats.
Banerjee, S; Chatterji, U; Chaudhuri-Sengupta, S; Maiti, BR; Nag, D; Nag, TC; Saha, I, 2007
)
1.29
"Arecoline treatment partly decreased the self-administration of morphine, it prevented the abstinence-induced decrease in body weight, and it reduced lever responding after protracted withdrawal (by 56%)."( A 24-h access I.V. self-administration schedule of morphine reinforcement and the estimation of recidivism: Pharmacological modification by arecoline.
Bain, JN; Buccafusco, JJ, 2007
)
1.26
"Arecoline-treated human gingival fibroblasts showed a more rounded appearance and detached at the higher concentrations."( Cytopathologic effects of arecoline on human gingival fibroblasts in vitro.
Chang, YC; Chou, LS; Chou, MY; Lii, CK; Tai, KW, 1999
)
1.32
"Arecoline treatment had no effect on brain incorporation of [3H]PA."( Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats.
DeGeorge, JJ; Nariai, T; Rapoport, SI; Williams, WM; Yamazaki, S, 1991
)
2.45
"Arecoline treatment did not appreciably alter the host resistance to endotoxin shock."( Influence of arecoline on immune system: II. Suppression of thymus-dependent immune responses and parameter of non-specific resistance after short-term exposure.
Rao, AR; Selvakumaran, M; Selvan, RS, 1991
)
1.37
"The arecoline-treated group, as hypothesized, exhibited a significantly greater reduction in number of crossings than the saline-treated groups following the course of swim stress."( Chronic swim stress enhances the motoric inhibiting effects of a muscarinic agonist.
Dilsaver, SC; Hoh, J; Jaeckle, RS; Miller, SH; Peck, JA; Traumata, D, 1990
)
0.76
"Treatment of arecoline in BMFs dose-dependently reduced gene expression of miR-200b, which corresponded with the decreased expression of miR-200b in fBMFs."( miR-200b ameliorates myofibroblast transdifferentiation in precancerous oral submucous fibrosis through targeting ZEB2.
Chang, YC; Hsieh, PL; Liao, YW; Yu, CC, 2018
)
0.83
"Treatment with arecoline (0.1-1.8 mg/kg) or nicotine (1.0-2.0 mg/kg) generally did not reverse the effects of scopolamine."( Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.
Field, MJ; Iversen, SD; Jennings, CA; Rupniak, NM; Steventon, MJ, 1989
)
0.62

Toxicity

A subchronic toxicity test was conducted in rats on the basis of a previous acute toxicity test to evaluate the safety of arecoline hydrobromide (Ah) The precise molecular mechanisms underlying the toxic effects ofArecoline deserve investigation.

ExcerptReferenceRelevance
" No adverse drug effects occurred."( Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.
Asthana, S; Berardi, A; Haxby, JV; Morris, PP; Raffaele, KC; Soncrant, TT, 1993
)
0.52
" Arecoline was also toxic to GK, but did not induce intracellular vacuolization."( Effects of areca nut, inflorescence piper betle extracts and arecoline on cytotoxicity, total and unscheduled DNA synthesis in cultured gingival keratinocytes.
Chan, CP; Chang, MC; Hahn, LJ; Hsieh, CC; Jeng, JH; Lin, BR, 1999
)
1.46
" The aim of this investigation was to study the growth and morphologic characteristics and toxic response of human pulp lines and to compare these parameters to those of human buccal mucosa fibroblasts."( Cultured pulp fibroblasts: are they suitable for in vitro cytotoxicity testing?
Maritz, JS; Olivier, A; van Wyk, CW, 2001
)
0.31
"The major alkaloid in the betel nut, arecoline, has been reported to be potent in inducing developmentally toxic effects by generally lowering the embryo weight and retarding development of the embryo."( Developmental toxicity of arecoline, the major alkaloid in betel nuts, in zebrafish embryos.
Chang, BE; Chen, CH; Kuo, MY; Liao, MH, 2004
)
0.9
" It shows strong correlation to the incidence of oral submucosal fibrosis, leukoplakia and oral cancer, and has also been found to impose toxic manifestations in immune, hepatic and other defense systems of the recipient."( Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice.
Bhattacharyya, A; Das, T; Dasgupta, R; Maiti, BR; Nag, TC; Pal, S; Sa, G; Saha, I, 2006
)
0.56
"The precise molecular mechanisms underlying the toxic effects of arecoline deserve investigation."( Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice.
Bhattacharyya, A; Das, T; Dasgupta, R; Maiti, BR; Nag, TC; Pal, S; Sa, G; Saha, I, 2006
)
0.8
" The present study was undertaken to characterize the toxic effects of arecoline in gene expression profiling on normal human gingival fibroblasts (HGF) using cDNA microarray and quantitative real-time reverse transcription PCR."( Characterization of arecoline-induced effects on cytotoxicity in normal human gingival fibroblasts by global gene expression profiling.
Chang, IS; Chen, PH; Chiang, HC; Chiang, SL; Ho, KY; Jiang, SS; Ko, YC; Tsai, YS; Tu, HP; Wang, YJ, 2007
)
0.9
" However, little is known about the toxic effect of BQ components on endothelial cells that play important roles for angiogenesis, carcinogenesis, tissue fibrosis, and cardiovascular diseases."( Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells.
Chang, JZ; Chang, MC; Chi, LY; Hsu, ML; Jeng, JH; Su, CY; Tseng, SK; Tseng, WY; Yeung, SY, 2012
)
1.82
"A subchronic toxicity test was conducted in rats on the basis of a previous acute toxicity test to evaluate the safety of arecoline hydrobromide (Ah), to systematically study its pharmacological effects and to provide experimental support for a safe clinical dose."( Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
Li, B; Li, J; Niu, J; Wei, X; Zhang, J; Zhou, X, 2015
)
0.99
" Arecoline has been reported to be the primary toxic constituent in the areca nut."( Arecoline induces cardiotoxicity by upregulating and activating cardiac hypertrophy-related pathways in Sprague-Dawley rats.
Chen, RJ; Chi-Kang Tsai, B; Day, CH; Ho, TJ; Huang, CY; Jine-Yuan Hsieh, D; Kumar, VB; Kuo, CH; Kuo, WW; Luk, HN; Yao, CH, 2022
)
3.07
"Agents that suppress the toxic effect of arecoline (a chemical present in the Areca nut fruit) have become a need of the hour owing to its several harmful effects on human beings."( Protective effect of the newly synthesized and characterized charge transfer (CT) complex against arecoline induced toxicity in third-instar larvae of transgenic
Jyoti, S; Khan, IM; Shakya, B; Shakya, S; Siddique, YH; Varshney, H, 2023
)
1.39

Pharmacokinetics

ExcerptReferenceRelevance
" In summary, the LC-MS/MS method described herein was fully validated and successfully applied to the pharmacokinetic study of arecoline hydrobromide tablets in dogs after oral administration."( Determination and pharmacokinetic studies of arecoline in dog plasma by liquid chromatography-tandem mass spectrometry.
Li, B; Li, JS; Li, JY; Liu, XW; Niu, JR; Wei, XJ; Yang, YJ; Zhang, JY; Zhou, XZ, 2014
)
0.87
" However, the pharmacokinetic parameters of these compounds have been little explored."( Pilot study of the pharmacokinetics of betel nut and betel quid biomarkers in saliva, urine, and hair of betel consumers.
Franke, AA; Lai, JF; Li, X, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effect of a drug combination on retention was found to be dependent on the particular drugs in the combination, the ratio and the dose administered."( Two-drug combinations of memory enhancers: effect of dose ratio upon potency and therapeutic window, in mice.
Cherkin, A; Flood, JF; Smith, GE, 1988
)
0.27
"To prove that synthetic Are combination with snail-killing drug Nic can increase the effects of snail-killing remarkably."( [Synergic effects of synthesis arecoline in combination with snail-killing drugs niclosamide].
Chen, YJ; Li, GL; Xu, SJ; Zhou, XG, 2006
)
0.62
"It proved that synthetic Are combination with snail-killing drug Nic might decrease Nic dosage and toxicity and increase the effects of snail-killing."( [Synergic effects of synthesis arecoline in combination with snail-killing drugs niclosamide].
Chen, YJ; Li, GL; Xu, SJ; Zhou, XG, 2006
)
0.62
" This study was designed to investigate the optimum arecoline content in CAN, using the "target constituent removal combined with bioactivity assay" strategy."( Using the "target constituent removal combined with bioactivity assay" strategy to investigate the optimum arecoline content in charred areca nut.
Gao, YX; Hu, MB; Liu, YJ; Peng, W; Wu, CJ; Yan, D, 2017
)
0.92

Bioavailability

ExcerptReferenceRelevance
" Physostigmine nasal bioavailability was 100% as compared with iv bioavailability, and that of arecoline was 85% when compared with bioavailability following im administration."( Intranasal absorption of physostigmine and arecoline.
Hussain, MA; Mollica, JA, 1991
)
0.76
" However, the mechanism underlying its oral bioavailability has not yet been studied."( Transport of the areca nut alkaloid arecaidine by the human proton-coupled amino acid transporter 1 (hPAT1).
Brandsch, M; Laug, L; Markwardt, F; Thondorf, I; Voigt, V; Zebisch, K, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A dose-response curve was determined for each of four drugs (arecoline, edrophonium, oxotremorine, tacrine) and for six possible two-drug combinations. Different concentrations of are coline were injected into Sprague-Dawley rat via intra-peritoneal method for 21 days.

ExcerptRelevanceReference
"Mice were given several atropine injections at a high dosage level."( Sensitivity changes to morphine and other drugs induced by cholinergic blockade.
Contreras, E; Quijada, L; Tamayo, L, 1975
)
0.25
" The dose-response curves of these compounds in the former were shifted to the right and/or abolished, suggesting decreased sensitivity of LEW/N hypothalami to these neurotransmitters."( Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone.
Aksentijevich, S; Bagdy, G; Bernardini, R; Calogero, AE; Chrousos, GP; Gold, PW; Smith, C; Sternberg, EM; Wilder, RL, 1992
)
0.28
" Addition of the muscarinic antagonists atropine or pirenzepine shifted the carbachol dose-response curves to the right, without decreasing the carbachol maximal stimulatory effects."( Effects of muscarinic agonists and depolarizing agents on inositol monophosphate accumulation in the rabbit vagus nerve.
Dunant, Y; Sierro, CD; Vitus, J, 1992
)
0.28
" At arecoline concentration of 10 mg/kg bw, there was a moderate reduction in DTH response, while no appreciable change was observed at a dosage of 5 mg/kg bw."( Influence of arecoline on immune system: II. Suppression of thymus-dependent immune responses and parameter of non-specific resistance after short-term exposure.
Rao, AR; Selvakumaran, M; Selvan, RS, 1991
)
1.21
" Diabetic mice have a shift to the left in the inverted U-shaped dose-response curve for memory retention produced by the acetylcholine agonist arecoline."( Characteristics of learning and memory in streptozocin-induced diabetic mice.
Flood, JF; Mooradian, AD; Morley, JE, 1990
)
0.48
" Dose-response analysis of peak and plateau phases of intracellular Ca2+ shows different agonist potencies for both phases, carbachol being more potent for the plateau phase."( Muscarinic-receptor-mediated changes in intracellular Ca2+ and inositol 1,4,5-trisphosphate mass in a human neuroblastoma cell line, SH-SY5Y.
Lambert, DG; Nahorski, SR, 1990
)
0.28
" Dose-response curves with either arecoline or histamine on isolated tracheae from these animals display increased maximal contractions, and decreased EC50 values."( Endotoxin-induced hyperreactivity of the guinea-pig isolated trachea coincides with decreased prostaglandin E2 production by the epithelial layer.
Engels, F; Folkerts, G; Nijkamp, FP, 1989
)
0.56
" Some combinations of cholinergic drugs enhance retention even though the total drug dosage is reduced by as much as 97% compared to the dose needed to improve retention when the same drugs are administered singly."( Two-drug combinations of memory enhancers: effect of dose ratio upon potency and therapeutic window, in mice.
Cherkin, A; Flood, JF; Smith, GE, 1988
)
0.27
" A dose-response curve was determined for each of four drugs (arecoline, edrophonium, oxotremorine, tacrine) and for each of the six possible two-drug combinations."( Memory enhancement: supra-additive effect of subcutaneous cholinergic drug combinations in mice.
Cherkin, A; Flood, JF; Smith, GE, 1985
)
0.51
" Positive results were obtained and a linear dose-response relationship was expressed when pregnant mice were treated with arecoline at dose levels of 20, 40 and 80 mg/kg and micronucleated polychromatic erythrocytes from fetal blood were subsequently analysed."( Transplacental micronucleus inducing ability of arecoline, a betel nut alkaloid, in mice.
Rao, AR; Sinha, A, 1985
)
0.73
" After several pilot dose-response studies, we administered 8 mg of the cholinergic agonist arecoline subcutaneously to eight pairs of normal volunteer identical twins and eight bipolar patients currently euthymic and unmedicated."( Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients.
Gershon, ES; Gillin, JC; Jimerson, DC; Lawrence, D; Nadi, NS; Nurnberger, JI; Simmons-Alling, S; Sitaram, N; Tamminga, C, 1983
)
0.73
" The frequency of aberrations showed a dose-response relationship."( Chromosome-breaking ability of arecoline, a major betel-nut alkaloid, in mouse bone-marrow cells in vivo.
Panigrahi, GB; Rao, AR, 1982
)
0.55
" granulosus infection in dogs currently relies on arecoline dosing and detailed examination of the purge for adult worms."( Diagnosis of canine echinococcosis: comparison of coproantigen and serum antibody tests with arecoline purgation in Uruguay.
Acuttis, A; Agulla, J; Borgues, C; Cabrera, P; Craig, PS; Gasser, RB; Paolillo, E; Parada, L; Parietti, S; Snowden, K, 1995
)
0.76
" During blinded, placebo-controlled, individualized optimal dosing for 5 days, verbal memory again improved in five of six responders but not in any non-responder."( Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.
Asthana, S; Berardi, A; Haxby, JV; Morris, PP; Raffaele, KC; Soncrant, TT, 1993
)
0.52
"25 microM), revealing a separation of the dose-response relationships."( A comparison between muscarinic receptor occupancy, inositol 1,4,5-trisphosphate accumulation and Ca2+ mobilization in permeabilized SH-SY5Y neuroblastoma cells.
Nahorski, SR; Safrany, ST, 1994
)
0.29
" Arecoline exposure for a week invoked dose-dependent effect on primary antibody forming cells to SRBC with a maximum reduction at the dosage of 20 mg/kg bw, a moderate reduction at 10 mg/kg bw and no effect at 5 mg/kg bw dose level."( Influence of arecoline on immune system: III. Suppression of B cell-mediated immune response in mice after short-term exposure.
Rao, AR; Selvan, RS,
)
1.41
"kg-1) shifted the dose-response curve of xylazine induced sedation to the right, hemicholinum-3 (3 micrograms icv), which inhibits the synthesis of acetylcholine, shifted the dose-response curve to the left."( [Antagonistic effects of cholinergic drugs on xylazine induced sedation].
Ding, RG; Huang, SJ; Yang, JS, 1993
)
0.29
" We report age-related changes in the drug dosage needed to improve 1 week retention in the P/8 but not R/1 line."( Age-related changes in the pharmacological improvement of retention in senescence accelerated mouse (SAM).
Flood, JF; La Reginna, M; Morley, JE,
)
0.13
" The dose-response curves of 2-butynyloxy, cyclopropylmethyloxy and hexyloxy compound together was the same as the response of each separately."( 1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover.
Hoss, W; Messer, WS; Periyasamy, S; Roknich, S; Sauerberg, P, 1995
)
0.57
" The results indicate that bicuculline (GABA antagonist), SKF38393 (DA agonist), and ST587 (NE agonist) facilitated retention with little change in the dose-response curves for P8 mice 4, 8, and 12 months of age."( Age-related changes in hippocampal drug facilitation of memory processing in SAMP8 mice.
Flood, JF; Harris, FJ; Morley, JE,
)
0.13
" A dose-response curve was constructed for each group of animals."( Heart rate responses to a muscarinic agonist in rats with experimentally induced acute and subacute chagasic myocarditis.
Arata de Bellabarba, G; Dávila, DF; Donis, JH; Gottberg, CF; Ramoni-Perazzi, P; Torres, A,
)
0.13
"It proved that synthetic Are combination with snail-killing drug Nic might decrease Nic dosage and toxicity and increase the effects of snail-killing."( [Synergic effects of synthesis arecoline in combination with snail-killing drugs niclosamide].
Chen, YJ; Li, GL; Xu, SJ; Zhou, XG, 2006
)
0.62
" At optimum concentration of arecoline determined from dose-response curve of the cytotoxicity, a large number of genes were significantly repressed than induced by arecoline in global gene expression profiling."( Characterization of arecoline-induced effects on cytotoxicity in normal human gingival fibroblasts by global gene expression profiling.
Chang, IS; Chen, PH; Chiang, HC; Chiang, SL; Ho, KY; Jiang, SS; Ko, YC; Tsai, YS; Tu, HP; Wang, YJ, 2007
)
0.95
" Both types of blocker weakened arecoline tremor, though the dose-response relationships were different for mono-and dications."( Involvement of ionotropic glutamate receptors in the appearance of arecoline tremor in mice.
Gmiro, VE; Lavrent'eva, VV; Lukomskaya, NY; Magazanik, LG; Starshinova, LA; Zhabko, EP, 2008
)
0.87
" However, it is safe to use Ah according to the clinically recommended dosing parameters."( Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
Li, B; Li, J; Niu, J; Wei, X; Zhang, J; Zhou, X, 2015
)
0.78
" Different concentrations of are coline (lowdosage: 5 mg/kg/day and high dosage 50 mg/kg/day) were injected into Sprague-Dawley rat via intra-peritoneal method for 21 days to create negative effects of arecoline on cardiomyocyte."( Arecoline induces heart injure via Fas/Fas ligand apoptotic pathway in heart of Sprague-Dawley rat.
Chen, MY; Chen, RJ; Chiu, PL; Day, CH; Huang, CY; Lee, HC; Lin, WY; Luk, HN; Padma, VV; Tsai, BC, 2021
)
2.25
" Arecoline at a low dosage (5 mg/kg/day) or a high dosage (50 mg/kg/day) was intraperitoneally injected to Sprague-Dawley rats for 21 days."( Arecoline induces cardiotoxicity by upregulating and activating cardiac hypertrophy-related pathways in Sprague-Dawley rats.
Chen, RJ; Chi-Kang Tsai, B; Day, CH; Ho, TJ; Huang, CY; Jine-Yuan Hsieh, D; Kumar, VB; Kuo, CH; Kuo, WW; Luk, HN; Yao, CH, 2022
)
3.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
muscarinic agonistAny drug that binds to and activates a muscarinic cholinergic receptor.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
tetrahydropyridine
enoate esterAn alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position.
pyridine alkaloid
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency0.31625.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.00000.100020.879379.4328AID588453
GLI family zinc finger 3Homo sapiens (human)Potency17.49330.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency27.31160.000221.22318,912.5098AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.61800.001022.650876.6163AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency3.35870.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency17.54340.001310.157742.8575AID1259252; AID1259255; AID1259256
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency3.01120.154917.870243.6557AID1346891
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency10.09400.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.03550.010039.53711,122.0200AID1479
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency1.00000.891312.067628.1838AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.54811.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)3.60000.00001.23267.7930AID140947; AID142394
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.99490.00000.690210.0000AID142519; AID142529; AID142531; AID142532; AID322941
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)30.50000.00001.15467.5858AID141875; AID142022
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki16.20650.00000.79519.1201AID141884; AID141885; AID141886; AID141887
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)68.91520.00052.773925.1700AID104017; AID141540; AID141541; AID141542; AID141543; AID141544; AID141554; AID141555; AID142022; AID382098; AID437586; AID477395
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki27.09630.00010.579710.0000AID141434; AID142343; AID142346; AID142347; AID142348; AID382098; AID437586; AID477395
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)18.51170.00052.891925.1700AID104017; AID141540; AID141541; AID141542; AID141543; AID141544; AID142022
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki2.77600.00011.48339.1400AID141729; AID142343; AID142346; AID142347; AID142348
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)18.51170.00052.747825.1700AID104017; AID141540; AID141541; AID141542; AID141543; AID141544; AID142022
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki2.22600.00010.68688.2600AID142014; AID142343; AID142346; AID142347; AID142348
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)18.51170.00052.780225.1700AID104017; AID141540; AID141541; AID141542; AID141543; AID141544; AID142022
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki2.19130.00010.66618.2600AID142343; AID142346; AID142347; AID142348
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)62.50000.00010.99178.0000AID142281
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki56.11710.00000.72926.9183AID142154; AID322942
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.27000.00000.12345.5000AID146461; AID146463
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)17.13310.00053.314249.5000AID104017; AID141540; AID141541; AID141542; AID141543; AID141544; AID142022; AID142806
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki1.83270.00010.58908.2600AID142343; AID142346; AID142347; AID142348; AID142958
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)81.40380.00001.403910.0000AID141040; AID141041; AID141052; AID141973
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki19.50870.00000.59729.1201AID141169; AID141179; AID322940
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.27000.00000.10825.5000AID146461; AID146463
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)Ki0.00440.00160.41173.1623AID141434; AID141435
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)34.50000.00011.01049.9280AID141349; AID141745
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki24.35000.00000.54057.7600AID141467; AID141470
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)IC50 (µMol)65.00000.00040.81213.8000AID141052
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)EC50 (µMol)5.01250.00000.737810.0000AID142379; AID142417
Muscarinic acetylcholine receptor M4Homo sapiens (human)EC50 (µMol)0.13000.00570.84656.6069AID141868
Muscarinic acetylcholine receptor M5Homo sapiens (human)EC50 (µMol)0.60000.05501.957010.0000AID142145
Muscarinic acetylcholine receptor M1Homo sapiens (human)EC50 (µMol)4.40150.00161.304310.0000AID141037; AID142284
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)EC50 (µMol)27.00000.27004.29006.9000AID141319
Muscarinic acetylcholine receptor M3Homo sapiens (human)EC50 (µMol)0.34000.00040.99355.9000AID141345
Muscarinic acetylcholine receptor M3Mus musculus (house mouse)EC50 (µMol)12.00009.90009.950010.0000AID141597
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)K app2.48660.00000.98246.2000AID142085; AID142087; AID142095; AID142096; AID142097; AID142098; AID142209; AID142210; AID142211; AID142212
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)K app2.48660.00000.98246.2000AID142085; AID142087; AID142095; AID142096; AID142097; AID142098; AID142209; AID142210; AID142211; AID142212
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)K app2.48660.00000.98246.2000AID142085; AID142087; AID142095; AID142096; AID142097; AID142098; AID142209; AID142210; AID142211; AID142212
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)K app2.48660.00000.98246.2000AID142085; AID142087; AID142095; AID142096; AID142097; AID142098; AID142209; AID142210; AID142211; AID142212
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)K app2.48660.00001.00846.2000AID142085; AID142087; AID142095; AID142096; AID142097; AID142098; AID142209; AID142210; AID142211; AID142212
Muscarinic acetylcholine receptor M3Mus musculus (house mouse)KL0.00090.00090.00460.0084AID141601
Muscarinic acetylcholine receptor M2Mus musculus (house mouse)KL0.00060.00060.00630.0120AID142666
Muscarinic acetylcholine receptor M2Mus musculus (house mouse)Km0.00240.00240.02420.0460AID142667
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (261)

Assay IDTitleYearJournalArticle
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345189Rat M1 receptor (Acetylcholine receptors (muscarinic))1989The Journal of pharmacology and experimental therapeutics, Feb, Volume: 248, Issue:2
Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID141597Tested against Muscarinic acetylcholine receptor M3 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID232369Ratio of Compound (IC50(nM) of QNB/ IC50(nM) of OXO-M)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID181414Dose producing 50% fall in rhythmic slow wave activity in anesthetized rats1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID141973Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M11998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID142666Binding affinity (low) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID141532In vitro ability to displace [3H]quinuclidinyl benzilate (QNB) from rat cerebral cortex Muscarinic acetylcholine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID142343The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M to muscarinic acetylcholine receptor in rat cerebral cortical membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID233564The ratio of Kapp([3H]-NMS) / Kapp([3H]-OXO-M) was determined1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Novel quinuclidine-based ligands for the muscarinic cholinergic receptor.
AID189461Stimulation of phosphoinositide (PI) metabolism in rat cortex at 100 uM1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID232606Ratio of IC50 QNB to that of OXO-M was determined1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID141179Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M1 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID101734Peripheral postsynaptic muscarinic activity by contraction of the guinea pig ileum.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142211In vitro binding affinity against cortical muscarinic acetylcholine receptor measured by displacement of [3H]NMS.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives.
AID141885Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M41998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID322940Binding affinity to human cloned muscarinic M1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
AID142212In vitro binding affinity against cortical muscarinic acetylcholine receptor measured by displacement of [3H]OXO-M.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives.
AID141057Inhibition of binding of [3H]- quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in membranes of CHO cells at 100 uM compound concentration2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142613M1 agonist activity estimated by rat superior cervical ganglion depolarization1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID112960Compound was tested for its ability to induce salivation in mice upon subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141601Binding affinity (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M3 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141602Maximum stimulation at Muscarinic acetylcholine receptor M3 expressed in A9 L cells1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141431Percent inhibition of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the presence of 300 uM GTP-gamma-S1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID142210In vitro binding affinity against muscarinic acetylcholine receptor from rat cortical homogenates using [3H]oxotremorine-M radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors.
AID142430Stimulation of cAMP in CHO cells expressing human m2 receptor1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID141544In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID141169Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M1 using [3H]QNB radioligand2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.
AID141886Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M4 in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141663In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]PZ from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID141745Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M31998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID142096Apparent binding affinity at rat cortical muscarinic acetylcholine receptor by the displacement of [3H]oxotremorine-M.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands.
AID141430Percent inhibition (low) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the absence of 300 uM GTP-gamma-S1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141319Tested against Muscarinic acetylcholine receptor M1 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID142805Inhibition of [3H]quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M2 in rat brain membrane1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID73733Effective concentration of compound for the agonistic activity on guinea pig ileum1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID230246Ratio of NMS/oxo-M apparent binding affinities (Kapp)1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
2-Methyl-1,3-dioxaazaspiro[4.5]decanes as novel muscarinic cholinergic agonists.
AID197332Neuronal postsynaptic muscarinic activity was measured by firing rate of the rat hippocampal CA1 neurons in M1 model1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142663Percent inhibition (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID477466Toxicity in po dosed Wistar rat assessed as mortality within 1 week2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID141436Maximum stimulation at Muscarinic acetylcholine receptor M1 expressed in A9 L cells1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141037In Vitro evaluation activity at the cloned Human Muscarinic acetylcholine receptor M1 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID112961Compound was tested for its ability to induce tremors in mice subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID477462Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat assessed as transfer latency period to reach from open arm to closed arm ends measured on day 2 at 0.5 mg/kg, po by elevated plus maze test2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID197176Central postsynaptic muscarinic activity was measured by slow depolarization of the rat cervical ganglion in M1 model1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID477463Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat at 0.5 mg/kg, po by Y maze test2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID197273Maximum stimulation of phosphatidyl inositol in rat hippocampal tissue, activity is expressed as percent of carbachol response1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID142300Stimulation of phosphoinositide hydrolysis in A9L cells expressing human m1 receptor1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID142417Stimulation of cAMP in CHO cells expressing human m2 receptor1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID230877Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID416537Inhibition of scopolamine-induced immediate working memory deficit in NMRI mouse at 1 mg/kg, ip by Y-maze test relative to control2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID382098Displacement of [3H]Quinuclidinyl benzilate from muscarinic M1 receptor in Wistar rat cortex synaptosomal membrane2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models.
AID196226Tested for agonist activity through assays of phosphoinositide (PI) metabolism in slices from rat cerebral cortex1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID193266Neuronal postsynaptic muscarinic activity was measured relative to muscurine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID141541Inhibition of [3H]oxotremorine-M binding to rat brain membrane Muscarinic acetylcholine receptor1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID101732Peripheral postsynaptic muscarinic activity was measured relative to muscarine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142154Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M5 using [3H]QNB radioligand2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.
AID141946Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes at 100 uM2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID104017Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID141041Ability to displace [3H]oxotremorine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID141848Ratio of ability to displace pirenzpine compared to ability to displace CD (non-selective muscarinic agonist).1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID477459Antiamnesic activity against scopolamine-induced dementia in Wistar rat assessed as basal latency period to reach shock free zone at 0.5 mg/kg, po2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID146463The compound was evaluated for percentage inhibition of binding of [3H]- nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in Rat Cerebral Cortical Membranes1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID437586Displacement of [3H]QNB from muscarinic M1 receptor in Wistar rat brain cortex membrane after 2 hrs by liquid scintillation counting2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models.
AID141559In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]oxotremorine-M (Oxo-M) as radioligand1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID477395Displacement of [3H]QNB from muscarinic M1 receptor in Wistar rat brain cortex after 2 hrs by liquid scintillation counting2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID226748Potency ratio of EC50 of the CHO cell lines to that of A9L cell lines was calculated.1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID141875In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M41997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID142299Stimulation of phosphoinositide hydrolysis in BHK cells expressing human m1 receptor1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID142368Ratio of geometric mean of the affinity constant (Kapp) of NMS/OXO-M1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives.
AID141566Displacement of [3H]pirenzepine (Pz) from rat hippocampus muscarinic acetylcholine receptor M11992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
AID113180In vivo antinociceptive activity was measured using mouse grid shock (MGS) assay in mice upon subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID142379In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M2 determined by receptor selection and amplification technology (R-SAT).1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID141130Contraction of guinea pig ileum by muscarinic AChR activation, which could be inhibited by application of atropine1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
A novel class of conformationally restricted heterocyclic muscarinic agonists.
AID142394In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M21997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID78071Maximal contraction compared to acetylcholine in isolated guinea pig ileum1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.
AID141040Ability to displace [3H]N-methylscopolamine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID141664In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]QNB from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID142095Apparent binding affinity to rat cortical muscarinic acetylcholine receptor by the displacement of [3H]N-methylscopolamine1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands.
AID142693Affinity for muscarinic receptor in rat brain was measured by inhibition of [3H](R)-quinuclidinyl benzilate (QNB) binding1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID232161Ratio of 50% fall in heart rate to that of in blood pressure in anesthetized rats1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID141729Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M3 in rat cerebral cortical membranes1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID142088Apparent binding affinity at Muscarinic acetylcholine receptor by displacing [3H]oxotremorine-M in rat cortex1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
2-Methyl-1,3-dioxaazaspiro[4.5]decanes as novel muscarinic cholinergic agonists.
AID176362Concentration required to relax phenylephrine-precontracted aortic rings by 50% in endothelium intact rat aorta1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID142022Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]-NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M41998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID166483In vitro inhibition of maximum twitch height in electrically stimulated rabbit vas deferens.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID142014Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M4 in rat cerebral cortical membranes1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID142529Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M21998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID141659In vitro affinity evaluated using [3H]- oxotremorine as radioligand in rat cerebral cortex for muscarinic acetylcholine receptor1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID141467Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M3 using [3H]QNB radioligand2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.
AID141576Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in rat cerebral cortical membranes at 100 uM concentration1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID141665In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]-QNB from the rat heart tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID225548Binding affinity against muscarinic receptor in rat brain membranes using oxotremorine-M as ligand1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID75929Agonist activity at muscarinic acetylcholine receptor in isolated guinea pig ileum.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.
AID141565Displacement of [3H]oxotremorine-M (Oxo-M) from rat hippocampus muscarinic acetylcholine receptor M11992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
AID230976Ratio of the effectivie concentrations against muscarinic M2 and muscarinic M1 receptors.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID9455Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID141574Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]OXO-M as the radioligand.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID142349Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]OXO-M (oxotremorine) as the radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID141554Ability to displace [3H]pirenzepine (pir) from muscarinic acetylcholine receptor M1 in rat cortical tissue.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID167809Efficacy at muscarinic acetylcholine receptor M1 measured by the ability to inhibit the electrically stimulated twitch of the rabbit vas deferens1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
AID142519Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M2 using [3H]QNB radioligand2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.
AID78308In vitro inhibition of force of contraction in guinea pig atria.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID167827In vitro inhibition of twitch height in electrically stimulated rabbit vas deferens1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID141887Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M4 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141052In vitro affinity against human Muscarinic acetylcholine receptor M1 using quinuclidynyl benzylate (QNB)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID142531The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M m2 toMuscarinic acetylcholine receptor M2 in membranes of CHO cells2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142281Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M51998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141581Percentage inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in Rat Cerebral Cortical Membranes1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID140993M2/M3 agonist activity estimated by contraction of isolated guinea pig ileum1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID229750Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID228728Ratio of the binding affinities against muscarinic M2 and muscarinic M1 receptors.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID232159Ratio of 50% fall in blood pressure to that of rhythmic slow wave activity in anesthetized rats1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID142958Inhibition of binding of [3H]quinuclidinyl benzilate to Muscarinic acetylcholine receptor M2 in rat cerebral cortical membranes1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID477461Antiamnesic activity against scopolamine-induced memory loss and learning impairment in Wistar rat assessed as transfer latency period to reach from open arm to closed arm ends measured on day 1 at 0.5 mg/kg, po by elevated plus maze test2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID141868In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M4 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID142087Affinity to displace radioligand [3H]oxotremorine (OXO) at muscarinic acetylcholine receptor from rat cortical homogenate.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and muscarinic activities of 1,2,4-thiadiazoles.
AID78185In vitro inhibition of maximum force of contraction in guinea pig atria.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID142097In vitro for its ability to displace [3H]NMS from muscarinic acetylcholine receptor in rat cortical homogenates1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Novel quinuclidine-based ligands for the muscarinic cholinergic receptor.
AID142284Stimulation of phosphoinositide hydrolysis in A9L cells expressing human m1 receptor1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
AID141599Percent inhibition (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M3 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141660In vitro affinity evaluated using [3H]- quinuclidinyl benzilate as radioligand in rat cerebral cortex for muscarinic acetylcholine receptor1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID477460Antiamnesic activity against scopolamine-induced dementia in Wistar rat assessed as latency period to improve memory at 0.5 mg/kg, po2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
AID141529In vitro ability to displace [3H]oxotremorine-M (OXO-M) from rat cerebral cortex Muscarinic acetylcholine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID167153Efficacy at muscarinic acetylcholine receptor M1 measured by the ability to inhibit the electrically stimulated twitch of the rabbit vas deferens1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
AID146461Inhibition of binding of [3H]nicotine to Nicotinic acetylcholine receptor alpha4-beta2 in rat cerebral cortical membranes at 100 uM concentration1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID142367Ratio of apparent binding affinities of NMS and Oxo-M1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands.
AID142145In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M5 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID142664Percent inhibition (medium) of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID142806Inhibition of [3H]quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M2 of rat heart1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID142347Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID230876Ratio of affinity versus antagonist [3H]-QNB divided by affinity versus agonist [3H]OXO-M2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142488Inhibition of specific [3H](R)-QNB binding to Muscarinic acetylcholine receptor in rat brain membranes1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141551In Vitro binding affinity to the muscarinic acetylcholine receptor site in rat brain by using [3H]QNB as the radioligand.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.
AID141661In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]- Oxo-M from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID142346Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142532Inhibition of [3H]- quinuclidinyl benzilate binding to human Muscarinic acetylcholine receptor M2 expressed in CHO cell membrane2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142667Binding affinity (medium) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M2 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID142917Ratio of [3H]N-methylscopolamine (NMS) to [3H]oxotremorine (OXO) at muscarinic acetylcholine receptor from rat cortical homogenate.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and muscarinic activities of 1,2,4-thiadiazoles.
AID142369The selectivity ratio of Kapp of NMS/OXO -M1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors.
AID176907Dose producing 50% fall in heart rate in anesthetized rats1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID322941Binding affinity to human cloned muscarinic M2 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
AID142348Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]-NMS (N-Methylscopolamine) as the radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID141470Inhibition of binding of [3H]quinuclidinyl benzilate to muscarinic receptors in membranes of CHO cells transfected with Muscarinic acetylcholine receptor M31998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID141585The binding affinity was measured as inhibition of binding of [3H]- quinuclidinyl benzilate to m3 Muscarinic acetylcholine receptor M3 in membranes of CHO cells2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID142742In vitro binding affinity for muscarinic M1 receptor by displacing [3H]Pirenzepine binding on rat brain homogenate1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID230833M-1 selectivity expressed as M-2/M-1 index (Ki in [3H]-QNB / Ki in [3H]PZ) was determined1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID141552In vitro Binding affinity was measured against Muscarinic acetylcholine receptor on rat brain membranes using [3H]oxotremorine-M1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141349In vitro affinity is evaluated, using quinuclidynyl benzylate (QNB) as radioligand in human cloned Muscarinic acetylcholine receptor M31997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID141472Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M3 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141560In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]pirenzepine (Pz) as radioligand1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID141540Ability to displace [3H]cis--2-methyl-5-((dimethylamino)methyl)-1,3-di oxolane from muscarinic acetylcholine receptor in rat cortical tissue.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID141542Inhibition of binding of radioactive N-propylbenzilycholine mustard ([3H]-PrBCM) to rat brain membranes1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
A novel class of conformationally restricted heterocyclic muscarinic agonists.
AID228726Muscarinic agonist index (Ki in [3H]QNB / Ki in [3H]-OXO-M) was determined1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID189455Ability to stimulate phosphoinositol metabolism was examined in the rat cerebral cortex at 100 uM1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID230727Ratio of the Ki (NMS) value to that of Ki (Oxo-M).1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID26318Dissociation constant (pKa)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
A novel class of conformationally restricted heterocyclic muscarinic agonists.
AID231956Ratio of displacement of NMS and Oxo-M from muscarinic receptor M12001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID142209In vitro binding affinity against muscarinic acetylcholine receptor from rat cortical homogenates using [3H]N-methylscopolamine as radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors.
AID193265Central postsynaptic muscarinic activity was measured relative to muscurine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID141884Binding affinity of compound was determined towards human Muscarinic acetylcholine receptor M4 using [3H]QNB radioligand2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.
AID322942Binding affinity to human cloned muscarinic M5 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
AID141555Inhibition of [3H]pirenzepine binding to rat brain membrane Muscarinic acetylcholine receptor M11988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID142098In vitro displacement of [3H]OXO-M from muscarinic acetylcholine receptor in rat cortical homogenates1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Novel quinuclidine-based ligands for the muscarinic cholinergic receptor.
AID119583Effect on salivation in mice, after intraperitoneal administration of 10 mg/kg, activity expressed as a score using a scale of 0-2.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID141435Binding affinity of [3H]-(R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the presence of 300 uM GTP-gamma-S1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141575Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]-Pz as the radioligand.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID141543In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID9450Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID78151Compound was tested for the antagonistic activity on guinea pig ileum1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID228962Muscarinic agonist index calculated as [IC50(QNB)/IC50(Oxo-M)] X 0.162 values1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.
AID9449Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141550In vitro binding affinity to muscarinic acetylcholine receptor site in rat brain assayed using [3H]oxotremorine-M as the radioligand.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.
AID176906Dose producing 50% fall in blood pressure in anesthetized rats1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID140947Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M21998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID232983Relative efficacy determined by agonist index.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID141434Binding affinity (low) of [3H](R)-QNB binding to Muscarinic acetylcholine receptor M1 expressed in A9 L cell line in the absence of 300 uM GTP-gamma-S1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141058Percentage affinity versus [3H]quinuclidinyl benzilate (antagonist) binding to Muscarinic acetylcholine receptor M1 in Rat Cerebral Cortical Membranes, (Kd=0.26 nM)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
AID9454Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID141345In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M3 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID142092Apparent binding affinity at v, by displacing [3H]N-methylscopolamine (NMS) in rat cortex1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
2-Methyl-1,3-dioxaazaspiro[4.5]decanes as novel muscarinic cholinergic agonists.
AID142085Ability to displace radioligand [3H]N-methylscopolamine (NMS) at muscarinic acetylcholine receptor from rat cortical homogenate.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and muscarinic activities of 1,2,4-thiadiazoles.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,017)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990357 (35.10)18.7374
1990's201 (19.76)18.2507
2000's167 (16.42)29.6817
2010's193 (18.98)24.3611
2020's99 (9.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.44 (24.57)
Research Supply Index7.03 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index107.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (1.80%)5.53%
Reviews36 (3.24%)6.00%
Case Studies6 (0.54%)4.05%
Observational0 (0.00%)0.25%
Other1,048 (94.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]